RSLS

ReShape Lifesciences Inc. Common Stock

RSLS

Delisted

RSLS was delisted on the 28th of December, 2018.

Back to rankings

Healthcare Medical Devices

Financial journalist opinion

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (Nasdaq: RSLS). The post-merger company will trade at the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol “HIND.” About Vyome Vyo.

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company's previously announced merger with ReShape Lifesciences (Nasdaq: RSLS), which is expected to take effect for marketplace purposes with the open of trading on Friday, August 15, 2025 under the nam.

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Vyome Announces New Board of Directors with Deep MIT and AI Ties

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ: RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND. The new Vyome board members, which in.

Vyome Announces New Board of Directors with Deep MIT and AI Ties

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

IRVINE, Calif.--(BUSINESS WIRE)---- $HIND--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol "HIND." “Vy.

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 23, 2025, it received formal notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq's stockholders equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed.

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced strategic headcount reduction and provided an update on the merger agreement with Vyome Therapeutics and asset purchase agreement with Biorad Medisys.

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

See News Rankings

Charts implemented using Lightweight Charts™